Thomas Shrader
Stock Analyst at BTIG
(1.62)
# 3,128
Out of 4,711 analysts
42
Total ratings
38.89%
Success rate
-4.53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Shrader
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALEC Alector | Maintains: Buy | $16 → $5 | $1.86 | +168.82% | 2 | Nov 26, 2024 | |
| ATHA Athira Pharma | Downgrades: Neutral | n/a | $0.58 | - | 3 | Sep 4, 2024 | |
| PCVX Vaxcyte | Maintains: Buy | $98 → $160 | $86.53 | +84.91% | 2 | Sep 3, 2024 | |
| OVID Ovid Therapeutics | Maintains: Buy | $11 → $5 | $1.00 | +400.45% | 2 | Jun 18, 2024 | |
| ACIU AC Immune | Initiates: Buy | $8 | $2.68 | +198.51% | 1 | May 31, 2024 | |
| PMN ProMIS Neurosciences | Initiates: Buy | $8 | $0.92 | +769.57% | 1 | Oct 3, 2023 | |
| DTIL Precision BioSciences | Maintains: Buy | $180 → $60 | $4.72 | +1,171.19% | 1 | Jul 28, 2023 | |
| BHVN Biohaven | Reiterates: Buy | $24 | $36.26 | -33.81% | 2 | Jun 6, 2023 | |
| ANNX Annexon | Maintains: Buy | $15 → $7 | $5.23 | +33.84% | 2 | May 25, 2023 | |
| COYA Coya Therapeutics | Initiates: Buy | $15 | $5.24 | +186.26% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $68 → $13 | $0.69 | +1,777.80% | 3 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $31 | $42.02 | -26.23% | 3 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $10 | $1.56 | +541.03% | 2 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $22 | $1.85 | +1,089.19% | 2 | Oct 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $14 | $4.40 | +218.18% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $13.21 | +286.07% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $2.68 | +497.01% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.75 | - | 1 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $21.45 | - | 2 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $58 | $7.94 | +630.48% | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $3.49 | -14.04% | 3 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $397 → $346 | $146.47 | +136.23% | 3 | Feb 21, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $0.32 | - | 1 | Jun 30, 2017 |
Alector
Nov 26, 2024
Maintains: Buy
Price Target: $16 → $5
Current: $1.86
Upside: +168.82%
Athira Pharma
Sep 4, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.58
Upside: -
Vaxcyte
Sep 3, 2024
Maintains: Buy
Price Target: $98 → $160
Current: $86.53
Upside: +84.91%
Ovid Therapeutics
Jun 18, 2024
Maintains: Buy
Price Target: $11 → $5
Current: $1.00
Upside: +400.45%
AC Immune
May 31, 2024
Initiates: Buy
Price Target: $8
Current: $2.68
Upside: +198.51%
ProMIS Neurosciences
Oct 3, 2023
Initiates: Buy
Price Target: $8
Current: $0.92
Upside: +769.57%
Precision BioSciences
Jul 28, 2023
Maintains: Buy
Price Target: $180 → $60
Current: $4.72
Upside: +1,171.19%
Biohaven
Jun 6, 2023
Reiterates: Buy
Price Target: $24
Current: $36.26
Upside: -33.81%
Annexon
May 25, 2023
Maintains: Buy
Price Target: $15 → $7
Current: $5.23
Upside: +33.84%
Coya Therapeutics
May 18, 2023
Initiates: Buy
Price Target: $15
Current: $5.24
Upside: +186.26%
Mar 28, 2023
Maintains: Buy
Price Target: $68 → $13
Current: $0.69
Upside: +1,777.80%
Mar 20, 2023
Maintains: Buy
Price Target: $26 → $31
Current: $42.02
Upside: -26.23%
Nov 14, 2022
Maintains: Buy
Price Target: $30 → $10
Current: $1.56
Upside: +541.03%
Oct 5, 2022
Maintains: Buy
Price Target: $15 → $22
Current: $1.85
Upside: +1,089.19%
May 24, 2022
Maintains: Buy
Price Target: $31 → $14
Current: $4.40
Upside: +218.18%
Apr 20, 2021
Initiates: Buy
Price Target: $51
Current: $13.21
Upside: +286.07%
Mar 8, 2021
Initiates: Buy
Price Target: $16
Current: $2.68
Upside: +497.01%
Feb 3, 2021
Downgrades: Neutral
Price Target: n/a
Current: $5.75
Upside: -
Oct 16, 2020
Downgrades: Neutral
Price Target: n/a
Current: $21.45
Upside: -
Sep 15, 2020
Maintains: Buy
Price Target: $51 → $58
Current: $7.94
Upside: +630.48%
Apr 3, 2020
Maintains: Buy
Price Target: $4 → $3
Current: $3.49
Upside: -14.04%
Feb 21, 2019
Downgrades: Hold
Price Target: $397 → $346
Current: $146.47
Upside: +136.23%
Jun 30, 2017
Downgrades: Hold
Price Target: n/a
Current: $0.32
Upside: -